NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
TOP NEWS
Charles River
»08/10/2009 [Company watch]
Charles River Shanghai Facility Wins Animal Care Accreditations

Charles River reported that its year-old Shanghai CRO facility has received three accreditations from organisations protecting the care of laboratory animals: the Association for Assessment and Accreditation of Laboratory Animal Care ((AAALAC)), the Canadian Council on Animal Care (CCAC) and the Shanghai Laboratory Animal Commission (SLAC).

 
by: ChinaBio Today Charles River reported that its year-old Shanghai CRO facility has received three accreditations from organisations protecting the care of laboratory animals: the Association for Assessment and Accreditation of Laboratory Animal Care ((AAALAC)), the Canadian Council on Animal Care (CCAC) and the Shanghai Laboratory Animal Commission (SLAC). The CRO is a joint venture between Charles River and Shanghai BioExplorer, with Charles River being the majority partner. Charles River opened its 60,000 square foot Shanghai preclinical facility last October. Charles River has said the facility will provide China-based preclinical CRO services to international biopharmas that are already Charles River clients, though it also will seek business from domestic biopharmas. Dr. Kewin Jin is the General Manager of Charles River Shanghai. Jin co-founded Shanghai BioExplorer in 2002. He was trained in medicine at the Shanghai Second Medical University, received his PhD in molecular biology at Rockefeller University and studied finance at Columbia University. “These three accreditations are a milestone in Charles River’s strategy to create a Centre of Excellence in China,” said James C. Foster, President, Chairman and Chief Executive Officer of Charles River in a statement. “As the leading international CRO with GLP capabilities in China, we are replicating the Company’s high standards of research, safety, humane care and laboratory best practices that globally distinguish Charles River.”

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.